Ashraf Reda

Never vote for any one اساند الاضعف واعشق المعارضه. لااحب ان اكون مع الاغلبيه ودايماً علي يسارك

[JACC Journals @JACCJournals]

Intensive blood pressure (BP) treatment, targeting office systolic BP to <120 mm Hg, produced modest benefits to health-related quality of life among hypertensive patients with high cardiovascular risk. https://t.co/Qn3Bwt9xYY

#GWICC #AHS2025 #ACCIntl #JACC #Hypertension #QoL

[Ashraf Reda @a_reda_55]

@JACCJournals This conclusion is misleading , 5 years is not enough to demonstrate statin efficacy in reducing CV events in patients with low or zero Ca score.

[National Lipid Association @nationallipid]

📣October's Lipid Panel: Diagnosis and Management of Patients with Lipoprotein X

📅 Tuesday, Oct. 28, 2025 | 🕗 8:00 PM ET

Join this month's panel for an interactive, case-based discussion on Lipoprotein X and practical clinical management. Earn CME/CE!

👉 Register now: https://t.co/gH6GEjMh6g

[Thomas Dayspring @Drlipid]

Download this incredibly important paper- first lipid-modulating drug to reduce a biomarker associated with AD @nationallipid @society_eas @ASPCardio @atherosociety @escardio @MenopauseOrg @PeterAttiaMD @NewAmsPharma @FamilyHeartFdn

[Prof Kausik Ray FMedSci @ProfKausikRay]

CETPi with obicetrapib is primarily a therapy for reducing LDL-C and thus atherosclerotic cardiovascular disease. Our latest publication shows attenuation of emerging biomarker of Alzheimer’s disease.
Exciting first steps https://t.co/JJRyk6t26S

[JACC Journals @JACCJournals]

This #JACC viewpoint agrees that dysfunctional adipose tissue is crucial to #HFpEF disease pathogenesis, and yet sex-based differences highlight that the #adipokine framework is only one piece of the puzzle: there is more to HFpEF than just fat alone. https://t.co/O6eWVlM0VW

[Federica Fogacci @FedericaFogacci]

🧠 Prof. Massimo Salvetti at #ATC2025 explores the powerful connection between the brain, stress, and cardiovascular health.
The heart is not only a pump — it’s a mirror of our neuroendocrine and emotional balance #CvPrev #CardioTwitter #CardioX

[European Society of Cardiology @escardio]

Issue 2 of the ESC Bench to Bedside webinar series is here!

If you're managing patients with HFpEF, this one’s for you.

Explore how GLP-1 receptor agonists (and GIP agonists) are opening up new possibilities in treatment. From picking the right patients to making confident, safe prescribing decisions – this latest episode of Bench to Bedside is packed with real-world insights you can use right away.

Ready to connect science to care?

Register now (free for everyone): https://t.co/d7vqNcWCif

#ESCWebinar #CardioMetabolicHealth #cardiology

[Ashraf Reda @a_reda_55]

@Ahmedata7777 and 50 %:reduction in high, very high and extreme risk

[Stroke AHA/ASA @StrokeAHA_ASA]

#STROKE: In an observational cohort study based on the MR CLEAN registry, bridging therapy with intravenous thrombolysis was associated with superior functional outcomes compared to EVT alone for patients with proximal M2 occlusions. #AHAJournals https://t.co/ulssXBhkmf

[Eric Topol @EricTopol]

Will A.I. lead to de-skilling of physicians?
And if so what can be done to preempt it?
@tberzin and I address this in a new @TheLancet piece
https://t.co/rK5Lf77YtK

[AJPC @AJPCardio]

🫀 Study spotlight: Utility of Coronary Artery Calcium Scoring in Low-Risk Patients — insights from the Multi-Ethnic Study of Atherosclerosis (MESA).

Read here 👉 https://t.co/fcivSOhx5b

#Cardiology #HeartHealth #MESA

[European Atherosclerosis Society @society_eas]

It’s happening! The EAS Advanced Course series on non-classical risk factors starts today in Gothenburg. Take a look at the programme and see the thought-provoking talks lined up. @stefano_romeo76 @HolvenKirsten

[AJPC @AJPCardio]

🔬 New finding: High Lipoprotein(a) is linked with elevated arachidonic acid levels.

Read more 👉 https://t.co/Np1xRY2r97

#CardioResearch #LipoproteinA #Lipidology

[Pablo Corral MD @drpablocorral]

👉Oral PCSK9 Inhibitors: A New Frontier in Lipid Management

👆A meta-analysis including >1,000 patients shows that oral PCSK9 inhibitors reduce key atherogenic lipoproteins by a clinically meaningful magnitude:

🔹 LDL-C ↓ 47.8%
🔹 ApoB ↓ 38.7%
🔹 Lp(a) ↓ 19.8%
🔹 Triglycerides ↓ 11.6%

Importantly, these agents demonstrated no increase in serious adverse events versus placebo.

💊 Oral PCSK9 inhibitors could transform lipid management — combining potent LDL-lowering efficacy with the convenience of oral dosing, potentially improving accessibility and adherence for patients with ASCVD or familial hypercholesterolemia.

🔗https://t.co/PZGjR3RJu0

@society_eas
@nationallipid

[العربية @AlArabiya]

لحظة توقيع الرئيس الأميركي #ترمب والوسطاء الوثيقة الشاملة لتنفيذ اتفاق #غزة خلال قمة السلام في شرم الشيخ
#قناة_العربية

[ONtvLIVE @ONliveEgypt]

الرئيس السيسي: قررنا إهداء الرئيس ترامب قلادة النيل الأرفع بين الأوسمة المصرية

#قمة_شرم_الشيخ_للسلام
#اتفاق_شرم_الشيخ
#SisiPeaceMaker

[Ashraf Reda @a_reda_55]

Join us in EAVA Cardiorisk 2025 12 - 15 November, Alexandria, Egypt
@atherosociety @society_eas

[Ashraf Reda @a_reda_55]

Jin us in cardiorisk 2025 12 - 15 November, Alexandria Egypt

[Raul Santos @rauldsf_santos]

Long-term experience with lomitapide treatment in patients with homozygous familial hypercholesterolemia: Over ten years of efficacy and safety data - Journal of Clinical Lipidology https://t.co/yE1Nd775b4